{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:31:56Z","timestamp":1789122716784,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41409-026-02932-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:27:55Z","timestamp":1783520875000},"page":"1238-1245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-3919","authenticated-orcid":false,"given":"Ryszard","family":"Swoboda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-131X","authenticated-orcid":false,"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclay","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-5308","authenticated-orcid":false,"given":"Desiree","family":"Kunadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-5814","authenticated-orcid":false,"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3732-5442","authenticated-orcid":false,"given":"Marie Therese","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-8025","authenticated-orcid":false,"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Giebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2932_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","volume":"60","author":"R Greco","year":"2025","unstructured":"Greco R, Ruggeri A, McLornan DP, Snowden JA, Alexander T, Angelucci E, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplant. 2025;60:1499\u2013525.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR2","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760\u20135.","journal-title":"Cancer"},{"key":"2932_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/ejh.14305","volume":"114","author":"N Steiner","year":"2025","unstructured":"Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, et al. Comparable results between 8 and 12 gray TBI in combination with fludarabine and post-transplant cyclophosphamide in MRD-negative but not in MRD-positive acute lymphoblastic leukemia patients transplanted in first complete remission. Eur J Haematol. 2025;114:79\u201388.","journal-title":"Eur J Haematol"},{"key":"2932_CR4","doi-asserted-by":"publisher","first-page":"e812","DOI":"10.1097\/HS9.0000000000000812","volume":"7","author":"A Spyridonidis","year":"2023","unstructured":"Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Sch\u00f6nland S, et al. Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e812.","journal-title":"Hemasphere"},{"key":"2932_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41409-023-01917-5","volume":"58","author":"S Giebel","year":"2023","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Aljurf M, Salmenniemi U, Labussi\u00e8re-Wallet H, et al. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2023;58:506\u201313.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41409-022-01841-0","volume":"58","author":"A Banet","year":"2023","unstructured":"Banet A, Bazarbachi A, Labopin M, Stocker N, Dul\u00e9ry R, Malard F, et al. Thiotepa, busulfan and fludarabine conditioning regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation. Bone Marrow Transplant. 2023;58:61\u201367.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR7","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1080\/10428194.2025.2548968","volume":"66","author":"D Amiri","year":"2025","unstructured":"Amiri D, Mirzaei M, Bahri T, Barkhordar M, Nejati N, Babakhani D, et al. Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen. Leuk Lymphoma. 2025;66:2448\u201356.","journal-title":"Leuk Lymphoma"},{"key":"2932_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41409-024-02363-7","volume":"59","author":"J Ahn","year":"2024","unstructured":"Ahn J, Yoon JH, Kwag D, Min GJ, Park SS, Park S, et al. Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2024;59:1413\u201322.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbmt.2016.11.001","volume":"23","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, et al. Clofarabine plus busulfan is an effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. Biol Blood Marrow Transplant. 2017;23:285\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2932_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ajh.24567","volume":"92","author":"S Eder","year":"2017","unstructured":"Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, et al. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia: a survey from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92:18\u201322.","journal-title":"Am J Hematol"},{"key":"2932_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0959-8049(02)00767-0","volume":"39","author":"I Fichtner","year":"2003","unstructured":"Fichtner I, Becker M, Baumgart J. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer. 2003;39:801\u20137.","journal-title":"Eur J Cancer"},{"key":"2932_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6690043","volume":"79","author":"JA Hartley","year":"1999","unstructured":"Hartley JA, O\u2019Hare CC, Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 1999;79:264\u20136.","journal-title":"Br J Cancer"},{"key":"2932_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/sj.bmt.1703215","volume":"28","author":"N Kr\u00f6ger","year":"2001","unstructured":"Kr\u00f6ger N, Schetelig J, Zabelina T, Kr\u00fcger W, Renges H, Stute N, et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2001;28:643\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211013985","volume":"12","author":"MA Slatter","year":"2021","unstructured":"Slatter MA, Gennery AR. Treosulfan-based conditioning for inborn errors of immunity. Ther Adv Hematol. 2021;12:20406207211013985.","journal-title":"Ther Adv Hematol"},{"key":"2932_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00277-021-04732-4","volume":"101","author":"R L\u00fcftinger","year":"2022","unstructured":"L\u00fcftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Ann Hematol. 2022;101:655\u201365.","journal-title":"Ann Hematol"},{"key":"2932_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","volume":"59","author":"KW Sykora","year":"2024","unstructured":"Sykora KW, Beier R, Schulz A, Cesaro S, Greil J, Gozdzik J, et al. Treosulfan vs busulfan conditioning for allogeneic BMT in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2024;59:107\u201316.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1182\/bloodadvances.2024014548","volume":"9","author":"K Kalwak","year":"2025","unstructured":"Kalwak K, Moser LM, P\u00f6tschger U, Bader P, Kleinschmidt K, Meisel R, et al. Comparable outcomes after busulfan- or treosulfan-based conditioning for alloHSCT in children with ALL: results of FORUM. Blood Adv. 2025;9:741\u201351.","journal-title":"Blood Adv"},{"key":"2932_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.19122","volume":"204","author":"A Cseh","year":"2024","unstructured":"Cseh A, Galimard JE, de la Fuente J, Isgro A, Zecca M, Garwer B, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: a study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2024;204:e1\u2013e5.","journal-title":"Br J Haematol"},{"key":"2932_CR19","first-page":"294.e1","volume":"32","author":"J Pyka","year":"2026","unstructured":"Pyka J, Metzdorf J, Reicherts C, Marx J, Leimk\u00fchler N, Schneider A, et al. Treosulfan-based conditioning ameliorates the impact of pretransplantation measurable residual disease-positivity in acute myeloid leukemia patients allografted in remission. Transpl Cell Ther. 2026;32:294.e1\u2013294.e11.","journal-title":"Transpl Cell Ther"},{"key":"2932_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41409-025-02702-2","volume":"60","author":"L Kolloch","year":"2025","unstructured":"Kolloch L, Berning P, Albring JC, Ronnacker J, Reicherts C, Call S, et al. Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning. Bone Marrow Transplant. 2025;60:1533\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41409-024-02456-3","volume":"60","author":"M Stelljes","year":"2025","unstructured":"Stelljes M, Sockel K, Floeth M, Schetelig J, Bornh\u00e4user M, Reicherts C, et al. Real-world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data. Bone Marrow Transplant. 2025;60:103\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR22","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/cancers16162859","volume":"16","author":"A Fraccaroli","year":"2024","unstructured":"Fraccaroli A, Stauffer E, Haebe S, Prevalsek D, Weiss L, Dorman K, et al. Treosulfan versus melphalan-based reduced intensity conditioning in HLA-haploidentical transplantation for patients \u2265 50 years with advanced MDS\/AML. Cancers. 2024;16:2859.","journal-title":"Cancers"},{"key":"2932_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41409-024-02295-2","volume":"59","author":"P Berning","year":"2024","unstructured":"Berning P, Kolloch L, Reicherts C, Call S, Marx J, Floeth M, et al. Comparable outcomes for TBI-based versus treosulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone Marrow Transplant. 2024;59:1097\u2013106.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR24","doi-asserted-by":"crossref","unstructured":"Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, et al. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024; 59:928\u201335.","DOI":"10.1038\/s41409-024-02269-4"},{"key":"2932_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41409-024-02241-2","volume":"59","author":"DW Beelen","year":"2024","unstructured":"Beelen DW, Iacobelli S, Koster L, Eikema DJ, van Biezen A, St\u00f6lzel F, et al. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients\u2014a clinical trial to registry data comparison. Bone Marrow Transplant. 2024;59:670\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR26","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","volume":"7","author":"F Saraceni","year":"2023","unstructured":"Saraceni F, Labopin M, Raiola AM, Blaise D, Rem\u00e9nyi P, Sor\u00e0 F, et al. Thiotepa-busulfan-fludarabine compared to treosulfan-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with acute myeloid leukemia in remission: a study from the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e952.","journal-title":"Hemasphere"},{"key":"2932_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41409-023-02028-x","volume":"58","author":"E Gavriilaki","year":"2023","unstructured":"Gavriilaki E, Sakellari I, Labopin M, Bornh\u00e4user M, Hamladji RM, Casper J, et al. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2023;58:1084\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41409-023-01965-x","volume":"58","author":"G Bug","year":"2023","unstructured":"Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt HC, Hilgendorf I, et al. Fludarabine\/TBI 8 Gy versus fludarabine\/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2023;58:710\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR29","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2022;57:1803\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41409-022-01777-5","volume":"57","author":"J Finke","year":"2022","unstructured":"Finke J, Schmoor C, Stelljes M, Burchert A, Dreger P, Hegenbart U, et al. Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial. Bone Marrow Transplant. 2022;57:1664\u201370.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ajh.26620","volume":"97","author":"DW Beelen","year":"2022","unstructured":"Beelen DW, Stelljes M, Rem\u00e9nyi P, Wagner-Drouet EM, Dreger P, Bethge W, et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97:1023\u201334.","journal-title":"Am J Hematol"},{"key":"2932_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41409-022-01646-1","volume":"57","author":"J Duque-Afonso","year":"2022","unstructured":"Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022;57:1269\u201376.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.17817","volume":"195","author":"A Shimoni","year":"2021","unstructured":"Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan- based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417\u201328.","journal-title":"Br J Haematol"},{"key":"2932_CR34","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/bmt.2015.174","volume":"50","author":"R Yerushalmi","year":"2015","unstructured":"Yerushalmi R, Shem-Tov N, Danylesko I, Avigdor A, Nagler A, Shimoni A. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. Bone Marrow Transplant. 2015;50:1526\u201335.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","volume":"142","author":"J Holowiecki","year":"2008","unstructured":"Holowiecki J, Giebel S, Wojnar J, Krawczyk-Kulis M, Markiewicz M, Holowiecka-Goral A, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol. 2008;142:284\u201392.","journal-title":"Br J Haematol"},{"key":"2932_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/sj.bmt.1705605","volume":"39","author":"M Schmidt-Hieber","year":"2007","unstructured":"Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2007;39:389\u201396.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR37","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/bmt.2015.202","volume":"50","author":"N Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger N, Bornh\u00e4user M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, et al. Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). Bone Marrow Transplant. 2015;50:1503\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2932_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"2932_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2932_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s002800050791","volume":"42","author":"RA Hilger","year":"1998","unstructured":"Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J, et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 1998;42:99\u2013104.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2932_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/gyno.1998.5103","volume":"71","author":"M Gropp","year":"1998","unstructured":"Gropp M, Meier W, Hepp H. Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol. 1998;71:94\u201398.","journal-title":"Gynecol Oncol"},{"key":"2932_CR43","first-page":"4209","volume":"6","author":"ME Scheulen","year":"2000","unstructured":"Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000;6:4209\u201316.","journal-title":"Clin Cancer Res"},{"key":"2932_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","volume":"35","author":"DW Beelen","year":"2005","unstructured":"Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005;35:233\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"2932_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","volume":"103","author":"J Casper","year":"2004","unstructured":"Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood. 2004;103:725\u201331.","journal-title":"Blood"},{"key":"2932_CR46","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","volume":"28","author":"J Casper","year":"2010","unstructured":"Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning. J Clin Oncol. 2010;28:3344\u201351.","journal-title":"J Clin Oncol"},{"key":"2932_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ajh.21240","volume":"83","author":"D Baronciani","year":"2008","unstructured":"Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M, et al. Treosulfan\/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol. 2008;83:717\u201320.","journal-title":"Am J Hematol"},{"key":"2932_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2141.2012.09228.x","volume":"159","author":"E Corker","year":"2012","unstructured":"Corker E, Astwood E, Williams J, Vora A. Treosulphan-based radiation-free myeloablative conditioning for allogeneic transplant in infant acute lymphoblastic leukaemia. Br J Haematol. 2012;159:104\u20136.","journal-title":"Br J Haematol"},{"key":"2932_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00277-014-2196-8","volume":"94","author":"H Boztug","year":"2015","unstructured":"Boztug H, Zecca M, Sykora KW, Veys P, Lankester A, Slatter M, et al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. 2015;94:297\u2013306.","journal-title":"Ann Hematol"},{"key":"2932_CR50","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02932-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:29Z","timestamp":1789119449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02932-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2932"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02932-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GB has received honoraria from Novartis, Jazz, BMS and Gilead and travel grants from Jazz, Gilead and Neovii. Other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the ALWP of the EBMT institutional review board and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Informed consent was obtained from all subjects.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}